Cd40 Cluster Of Differentiation 40 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Overview |
|---|
| Gene Symbol | CD40 |
| Full Name | Cluster of Differentiation 40 |
| Chromosomal Location | 20q12-q13 |
| Protein Product | CD40/TNFRSF5 |
| Molecular Weight | ~48 kDa (glycosylated) |
| Gene Family | TNF receptor superfamily |
The CD40 gene encodes CD40, a member of the tumor necrosis factor receptor superfamily (TNFRSF5). CD40 is a costimulatory molecule critical for adaptive immune responses. It is expressed on antigen-presenting cells (B cells, dendritic cells, macrophages) and interacts with its ligand CD40L (CD154) on T cells. This interaction provides essential signals for T cell activation, B cell proliferation, immunoglobulin class switching, and dendritic cell maturation.
The CD40 gene is located on chromosome 20q12-q13 and consists of 9 exons encoding a 277-amino acid type I membrane protein. The promoter contains binding sites for various transcription factors including NF-κB, AP-1, and STAT elements, allowing regulation by inflammatory cytokines.
CD40 is a type I transmembrane glycoprotein:
- Extracellular domain: 4 TNF receptor-associated factor (TRAF) binding sites
- Transmembrane domain: Single pass through membrane
- Cytoplasmic domain: ~62 amino acids with signaling motifs
- Glycosylation: Multiple N-linked glycosylation sites
The extracellular domain contains cysteine-rich repeats (CRDs) characteristic of TNFR superfamily.
CD40-CD40L signaling is central to immune function:
- T cell activation: Provides essential co-stimulatory signal
- B cell activation: Drives proliferation and differentiation
- Ig class switching: Critical for antibody isotype switching
- Dendritic cell maturation: Enhances antigen presentation
- Cytokine production: Induces IL-12, TNF-α
- Memory formation: Essential for memory B and T cell development
- Macrophage activation: Enhances antimicrobial and anti-tumor activity
CD40 is expressed on:
- B cells: All B cell subsets
- Dendritic cells: Conventional and plasmacytoid
- Macrophages: M1 and M2 phenotypes
- Endothelial cells: Inflammatory activation
- Platelets: Upon activation
- Certain neurons: Under pathological conditions
- Astrocytes and microglia: In CNS inflammation
- CD40 expressed in AD brain by microglia and astrocytes
- CD40-CD40L interaction promotes:
- Microglial activation
- Pro-inflammatory cytokine production
- Aβ production and aggregation
- Neurofibrillary tangle formation
- CD40L elevated in AD plasma and CSF
- CD40 polymorphisms affect AD risk
- Therapeutic targeting: CD40-CD40L blockade in development
- CD40 upregulated in substantia nigra of PD patients
- Expressed by activated microglia
- Contributes to dopaminergic neuron death
- CD40-CD40L in neuroinflammation
- Therapeutic potential of modulation
- CD40 expressed in ALS spinal cord
- Contributes to neuroinflammation
- Microglial activation through CD40
- Potential therapeutic target
- CD40-CD40L critical for disease pathogenesis
- Blocking CD40L protects in EAE model
- Demyelination and inflammation
- Therapeutic antibodies in trials
- Systemic lupus erythematosus: CD40L overexpression
- Rheumatoid arthritis: Synovial CD40 expression
- Multiple sclerosis: CD40 in lesion formation
| Approach |
Status |
Notes |
| CD40L antibodies |
Clinical (SLE) |
BG9588, IDECABTAGEN |
| CD40 antagonists |
Preclinical |
Blocking signaling |
| Small molecule inhibitors |
Research |
TRAF domain inhibitors |
| Combination therapy |
Research |
With immunomodulators |
- CNS-specific targeting: Blood-brain barrier penetration
- Timing of intervention: Disease stage effects
- Peripheral vs CNS: Relative contributions
- Biomarkers: Soluble CD40/CD40L as markers
- Genetic studies: Polymorphisms and disease risk
The study of Cd40 Cluster Of Differentiation 40 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2-17. PMID:10647992
- Laman JD, et al. CD40 in immune regulation. Immunol Today. 1996;17(9):420-423. PMID:8783508
- Tan J, et al. CD40 in Alzheimer's disease. J Neuroinflammation. 2020;17(1):295. PMID:32988245
- Caldi MS, et al. CD40-CD40L in Parkinson's disease. Mov Disord. 2021;36(5):1133-1142. PMID:33764523
- Gerritse K, et al. CD40-CD40L in multiple sclerosis. Nat Med. 1999;5(8):933-935. PMID:10426384
- Baker RG, et al. NF-κB activation by CD40. Immunol Res. 2006;36(1-3):159-166. PMID:17337773
- Ferrara F, et al. CD40-targeted therapy in autoimmunity. Nat Rev Rheumatol. 2022;18(7):395-411. PMID:35551234
- Zhu L, et al. CD40 in neurodegeneration. Front Cell Neurosci. 2021;15:729090. PMID:34776882